Nicotinamide riboside

导读：中国线粒体医学行业发展现状分析 中国线粒体医学行业现状与趋势分析 来源：罗辑医疗知识星球，医健趋势，药械出海 中国线粒体医学行业正处于“从基础研究迈向产业化应用”的关键转折期。研究范畴已由传统的遗传性线粒体疾病，拓展至心衰、阿尔茨海默病、2型糖尿病、青光眼、卵巢功能衰退、免疫衰老等广泛衰老相关疾病；核心路径聚焦“检测–干预–再检测”闭环生态，在靶向NAD+代谢的药物研发与全周期健康服务方面取得全球性突破。政策支持、老龄化加速与健康消费升级共同驱动行业发展，但整体仍处早期阶段，面临技术转化、市场教育与支付体系等挑战。 一、行业定义与范畴演进 科学内涵 线粒体医学是依托线粒体生理与病理机制，为疾病诊断、预防和治疗提供新策略的交叉学科，核心靶点为维持细胞能量与稳态的线粒体。 范畴重大拓展 传统领域：原发性线粒体遗传病（如MELAS、LHON），由mtDNA/nDNA缺陷所致。 现代核心：自2013年“线粒体功能障碍”被确立为衰老标志后，研究延伸至多种获得性慢性病——包括心血管疾病（心衰、缺血再灌注损伤）、神经退行性疾病（阿尔茨海默病、帕金森病）、代谢性疾病（2型糖尿病、非酒精性脂肪肝）、年龄相关眼科疾病（青光眼、AMD）、生殖系统衰老及免疫衰老等。 终极应用：切入万亿级抗衰老与主动健康管理市场，推动健康寿命延长。 二、行业发展驱动因素 需求端（根本动力） 人口深度老龄化：2024年中国65岁及以上人口达2.2亿（占比15.8%），2030年将升至2.7亿，衰老相关疾病负担催生源头干预需求。 健康观念升级：从“治病”转向“防病”，从“活得久”转向“活得好”，健康消费持续增长。 疾病谱变化：慢性病成主要健康威胁，线粒体功能障碍为其共性病理机制之一，成为理想干预靶标。 供给端（技术突破） 基础研究积累：国家自然科学基金对线粒体相关项目资助稳居医学类前三，机制解析成果丰硕。 关键技术成熟：多组学技术、基因检测、NAD+/ATP/Sirtuins等生物标志物检测、细胞/基因治疗及线粒体移植，为精准评估与干预提供支撑。 政策端（强力催化） 国家战略引领：“积极应对人口老龄化”上升为国家战略，《关于发展银发经济增进老年人福祉的意见》首次提出“发展抗衰老产业”，鼓励基因技术、再生医学与分子诊断在线粒体医学领域的应用。 产业与监管支持：创新药械审评审批加速；《生物医学新技术临床研究和临床转化应用管理条例》为线粒体移植等前沿技术转化提供制度框架。 三、产业链与市场现状分析 产业链闭环初步形成 行业围绕“检测–干预–再检测”构建核心生态链，实现精准化、阶梯式健康管理。 检测端：精准干预起点，涵盖线粒体基因组测序、氧耗率/膜电位/ATP生成功能检测、NAD+水平及ATP、Sirtuins、CD38等标志物检测；当前主要在科研及高端健康管理机构开展。 干预端：产业价值核心，形成三级体系： 营养干预（基础）：以NMN/NR等NAD+前体及抗氧化剂为主，面向健康/亚健康人群，市场教育度高； 药物干预（核心）：针对已出现功能障碍的疾病状态； 线粒体移植（前沿）：作为严重损伤替代疗法，康诺生物与复旦大学附属中山医院已在血管病变中开展临床探索，被视为继干细胞后的下一代再生医学方向。 再检测端：用于动态评估干预效果并调整治疗方案，是提升服务闭环与客户粘性的关键环节，目前尚未普及。 代表性进展 全球唯一获批NAD+药物：康诺生物“恩艾地®”（注射用辅酶I），获批用于白细胞减少、冠心病，并被多部延缓衰老及衰老相关疾病指南共识收录。 在研创新药：康诺生物KN-19ND-L1（抗心衰，II期临床）、艾美斐IPG8294（NAD+水解酶抑制剂，I期临床）。 市场竞争格局 国际企业：Chromadex（Niagen®）、Stealth BioTherapeutics（Elamipretide）、Minovia Therapeutics在线粒体移植等领域先行。 国内领先企业： 康诺生物：全产业链标杆，覆盖检测试剂盒、Aurea Mito™营养品、“恩艾地®”药物、创新药管线及线粒体移植临床研究，构建最完整商业闭环； 其他生物科技公司：如艾美斐生物等，聚焦NAD+水解酶等特定靶点研发。 医疗机构探索：解放军总医院、湘雅医院等已开设“抗衰老门诊”或“长寿门诊”，推动理念临床落地与模式验证。 四、当前发展面临的挑战 科学认知与市场教育不足：公众及部分医务人员对线粒体医学概念模糊，易与传统老年病或医美抗衰混淆，教育成本高。 技术转化与临床验证瓶颈：线粒体移植、基因编辑等技术多处于实验室或早期临床阶段，长期安全性、有效性及标准化工艺亟待大规模验证。 支付体系尚未建立：除部分适应症纳入医保外，多数检测、营养干预及高端健康管理服务为自费项目，价格高昂制约普及。 行业标准与监管缺失：检测方法标准化、营养补充剂功效宣称、细胞治疗产品监管等领域尚无统一规范。 专业人才极度稀缺：亟需融合细胞生物学、临床医学、营养学与数据科学的复合型人才，培养体系几近空白。 五、结论与现状总结 中国线粒体医学行业现状可概括为：“前景广阔，方兴未艾；点上有突破，面上待整合；科研有基础，产业刚起步”。 科研层面：基础研究与国际同步，在NAD+药物等应用转化上实现全球性突破，具备引领潜力。 产业层面：康诺生物等企业正尝试构建全产业链平台，但整体规模小、渗透率低，商业模式仍在探索中。 市场层面：需求真实且巨大，有效供给不足；当前聚焦高净值人群健康消费及部分严肃医疗场景，尚未大众化普及。 行业正处在产业化爆发的“前夜”。下一阶段的关键，在于打通“科学突破–技术创新–可支付商业模式–普惠化推广”链条，真正实现从实验室到消费者、从医院到家庭的全价值链贯通。

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research program has surpassed 300 material transfer agreements (MTAs) with investigators and research institutions around the world, marking a major milestone for what the Company believes is the most extensive dedicated NAD+ research support program in the world. Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Advancing Its Pioneering Legacy in NAD+ Science Rob Fried, CEO, Niagen Bioscience, commented, “Reaching more than 300 MTAs reflects the growing scientific momentum behind our patented nicotinamide riboside (NR) ingredient, Niagen®. This program has contributed to 45 published clinical studies, making Niagen the most extensively researched patented NAD-boosting ingredient in the world. Across clinical and preclinical research, Niagen has consistently been shown to elevate NAD+ safely and effectively, reinforcing the strong scientific foundation behind our ingredient.” Since its founding more than eleven years ago, Niagen Bioscience’s external research program has advanced the science of Niagen and evolved into a unique, industry-leading platform for independent NAD+ research. Surpassing 300 MTAs signals accelerating scientific interest in NAD+ and reflects how NAD+ biology has moved into the mainstream of healthy aging research, not only among consumers but across leading academic and clinical institutions worldwide. These agreements have helped generate 45 peer-reviewed published clinical studies on Niagen, with over 90% investigator-initiated and third-party funded, underscoring the rigor, independence, and credibility of the science. Yasmeen Nkrumah-Elie, PhD, Global Director of External Research, stated, “As NAD+ becomes increasingly recognized as fundamental to cellular health, scientific interest in effective NAD+ augmentation continues to grow. Through our external research program, investigators worldwide are turning to Niagen as the trusted NAD+ booster for rigorous, independent research, and we are proud to support both established and next-generation scientists exploring its potential across aging and disease.” Through the program, third-party investigators from leading institutions worldwide, including the National Institutes of Health (NIH), Mayo Clinic, Harvard University, and Cambridge University, request Niagen for clinical and preclinical research because it is the most efficient, effective, and high-quality NAD+ booster available. The program’s body of work has deepened understanding of NAD+’s role in cellular health, metabolic health, inflammation, cardiovascular health, neurodegeneration, liver health, muscle health, and rare diseases such as Ataxia Telangiectasia (AT), and demonstrates how Niagen supports NAD+ augmentation across these areas. Ongoing studies through the program continue to expand into high-impact areas of unmet need, including premature cardiovascular aging associated with adverse childhood experiences, inflammatory bowel disease such as ulcerative colitis, and maternal health, including the potential galactagogue effects of Niagen in mothers with premature births. Noteworthy scientific milestones to date include: Guzmán-Vélez et al., 2025 found that Niagen supplementation in the first-ever randomized, double-blind, placebo-controlled trial in individuals with long COVID significantly increased NAD+ levels and showed within-group improvements in fatigue, depression, and sleep quality. Presterud et al., 2023 demonstrated the potential of Niagen in ataxia telangiectasia (AT), with improvements in AT scores, immunoglobulins, whole-blood NAD+ levels, neuromotor coordination, and eye movements; this body of research through the external research program helped lead Niagen Bioscience to receive exclusive U.S. FDA Orphan Drug and Rare Pediatric Disease designations for NR for the treatment of AT. Han et al., 2023 demonstrated that elevating NAD+ with Niagen reduced inflammatory signaling in healthy subjects and immune cells derived from psoriasis patients, contributing to what has now grown to 7 clinical studies demonstrating the anti-inflammatory benefits of Niagen in both healthy and disease populations ( Elhassan et al., 201 9 , Zhou et al., 2020 , Remie et al., 2020 , Wu et al., 2022 , Brakedal et al., 2022 , Wang et al., 2022 , Han et al., 2023 ). The program now includes agreements with more than 200 institutions across 34 countries and has contributed to more than 225 peer-reviewed publications, including 45 published human clinical studies on Niagen. Niagen Bioscience estimates the program has generated more than $200 million in third-party research value or funding, underscoring the substantial outside investment researchers and institutions have made in studying Niagen and NAD+ biology. The program has also resulted in a patent portfolio of over 50 granted patents related to Niagen and other NAD+ precursors. Niagen Bioscience's external research program is believed to be the only program in the U.S. dietary supplement space supporting investigators, physicians, scientists, and academic institutions at this scale to advance the science of NAD+ and Niagen. What began as an early commitment to scientific rigor has evolved into a global research ecosystem that benefits not only Niagen Bioscience but the broader NAD+ category. The Company expects the external research program to continue expanding into new institutions, geographies, therapeutic areas, and delivery modalities as interest in NAD+ biology grows and researchers seek to better understand the role of Niagen in health, resilience, and aging. The program is also expected to expand into new areas of investigation, including topical applications, intravenous and injectable administration with pharmaceutical-grade Niagen, and the evaluation of additional novel NAD+ precursors. For additional information on Niagen, visit www.niagenbioscience.com. About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published. †Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025) Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continue,” “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those described. These risks and uncertainties include, but are not limited to, inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; including unanticipated developments in and risks related to the Company’s ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company’s ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company’s ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company’s ability to maintain and enforce the Company’s existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; mislabeling or other misleading marketing practices by competitors; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q as filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.